COVID-19 pulmonary infection in erythrodermic psoriatic patient with oligodendroglioma: safety and compatibility of apremilast with critical intensive care management
Mugheddu C.First
Member of the Collaboration Group
;Pizzatti L.Second
Member of the Collaboration Group
;Atzori L.
Penultimate
Writing - Review & Editing
;Rongioletti F.Last
Supervision
2020-01-01
Abstract
Novel coronavirus 2019 (SARS-CoV2) pandemic has particularly affected Italy, with a profound impact on the therapeutic strategy for complex disorder such as psoriasis, whose extensive skin damage might expose to an increased infective risk compared to the general population. Psoriasis treatment relies on immunosuppression, and although most experts agree that the benefit-to risk-ratio is in favor of maintaining selective biologic therapies, and small molecules such as apremilast, they recommend dismission if severe COVID-19 symptoms occur.File | Size | Format | |
---|---|---|---|
apremilast covid oligodendroglioma.pdf Solo gestori archivio
Type: versione editoriale
Size 552.3 kB
Format Adobe PDF
|
552.3 kB | Adobe PDF | & nbsp; View / Open Request a copy |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.